Last reviewed · How we verify

NCT04999423: SEALANT

LVIS™ Evo™ and HydroCoil® Embolic System for Intracranial Aneurysm Treatment

Active, enrolled Last updated 7 January 2025
What this trial tests

trial testing LVIS EVO and HydroCoil Embolic System in Intracranial Aneurysm in 206 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
14 January 2022
Primary endpoint
1 March 2025
1 December 2026

Quick facts

Lead sponsorMicrovention-Terumo, Inc.
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment206
Start date14 January 2022
Primary completion1 March 2025
Estimated completion1 December 2026
Sites19 locations across France, Italy, Belgium, United Kingdom, Germany

Drugs / interventions tested

Conditions studied

Sponsor

Microvention-Terumo, Inc. — full company profile →

Who can join

18 and older, any sex, with Intracranial Aneurysm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective multicenter international single-arm observational study to demonstrate that use of stent-assisted coiling with LVIS™ Evo™ and HydroCoil® Embolic System (HES) in intracranial aneurysm treatment is effective and safe when assessed at 1 year after the procedure

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Intracranial Aneurysm

Currently open trials in the same condition.

Other Microvention-Terumo, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04999423.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing